Education
About Us
Working with TipRanks
Follow Us
Cipher Pharmaceuticals (CPHRF)
OTHER OTC:CPHRF
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.16Last Year’s EPS
0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -14.61%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a strong growth narrative driven by the Natroba acquisition and Canadian product portfolio, leading to significant revenue and EBITDA growth. However, this was somewhat offset by declines in licensing revenue, particularly from Absorica, and increased expenses. The company's strategic debt repayment and pursuit of growth opportunities provide a balanced outlook.Company Guidance
During the first quarter of 2025, Cipher Pharmaceuticals reported total net revenue of $12 million, marking a 105% increase from the same period in 2024, largely due to the acquisition of the Natroba business. Natroba generated $6.7 million in revenue, achieving gross margins of $5.8 million or approximately 87% when excluding non-cash adjustments. The company's base business yielded $5.3 million in revenue, a 9% decline from the previous year, though Canadian product sales rose by 41%. Total adjusted EBITDA was $6.2 million, up by 73%, with a cash balance of $22 million and a reduced debt of $25 million after a $15 million repayment. The company highlighted its four-fold growth strategy for Natroba, including expansion in the US, a planned launch in Canada, global out-licensing, and acquiring complementary products.Strong Revenue Growth
Total net revenue increased by 105% to $12 million in Q1 2025 compared to the same period in 2024, largely due to the acquisition of the Natroba business.
Natroba Business Performance
Natroba generated $6.7 million in revenue with a gross margin of approximately 87%, positioning the business well for upcoming warmer months.
Canadian Product Portfolio Growth
Canadian product revenue increased by 41% compared to the same quarter in the prior year, contributing to overall product revenue growth.
Adjusted EBITDA Increase
Adjusted EBITDA rose by 73% to $6.2 million due to the Natroba acquisition and growth in the Canadian product portfolio.
Debt Repayment
A repayment of $15 million was made on the revolving credit facility, reducing the outstanding debt to $25 million.
CPHRF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CPHRF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $10.54 | $9.97 | -5.41% |
Mar 18, 2025 | $8.37 | $9.43 | +12.66% |
Nov 07, 2024 | $11.08 | $10.03 | -9.48% |
Aug 08, 2024 | $9.88 | $10.52 | +6.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cipher Pharmaceuticals (CPHRF) report earnings?
Cipher Pharmaceuticals (CPHRF) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Cipher Pharmaceuticals (CPHRF) earnings time?
Cipher Pharmaceuticals (CPHRF) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPHRF EPS forecast?
CPHRF EPS forecast for the fiscal quarter 2025 (Q2) is 0.16.